| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2015/043 | ||
|---|---|---|---|
| Date of filing | 21/07/2015 | ||
| Notification of Application Published | 26/08/2015 | ||
| Status | Rejected | ||
| Notification of Grant Published | |||
| Date of Expiry of SPC | |||
| Applicant |
Newron Pharmaceuticals S.p.A. Via Antonio Meucci, 3 20091 Bresso (MI) ITALY |
||
| Patent Number | 1613296 | ||
| Title of Invention | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | ||
| Date of Expiry of Patent | 07/04/2024 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Safinamide for use in combination with levodopa/PDI, and optionally with other PD medicinal products, for the treatment of Parkinson's Disease. | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/14/984/001-010 | ||
| Authorisation Date | 24/02/2015 | ||
| Identity of Product Authorised | Xadago - Safinamide | ||
| Address for Service |
Anne Ryan & Co 2 Crofton Terrace Dun Laoghaire Co. Dublin A96 V6P7 IRELAND |
||
| Renewal Fees | |||
| 27/07/2015 | Request for grant a Supplementary Protection Certificate filed on 21/07/2015, numbered 2015/043. | ||
| 14/04/2020 | Change of address of applicant(s) from Newron Pharmaceuticals S.p.A., Via L. Ariosto, 21, 20091 Bresso(MI), Italy to Newron Pharmaceuticals S.p.A., Via Antonio Meucci, 3, 20091 Bresso (MI), Italy recorded on 10/04/2020. | ||
| 04/04/2024 | Request for grant of Supplementary Protection Certification No. 2015/043 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||